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Abstract
The FRAXA and FRAXE alleles of the FMR1 and FMR2 genes located on
the X chromosome contain varying numbers of trinucleotide repeats. Large
numbers of repeats at FRAXA (full mutations) manifest as Fragile X
syndrome, associated with mental impairment that affects males more
severely. In this paper, we present the dataset of frequencies of FRAXA
and FRAXE repeat size extracted from DNA samples collected from boys
enrolled in the Avon Longitudinal Study of Parents and Children (ALSPAC).
DNA data were extracted from samples collected in ALSPAC clinics from
several types of samples: cord blood, venepuncture blood taken at 43
months, 61 months, seven years or nine years. The DNA was amplified at
FRAXA and FRAXE using fluorescent PCR in the Wessex Regional
Genetics Laboratory, Salisbury District Hospital. The mean repeat size for
FRAXA is 28.92 (S.D. 5.44), the median 30 and the range 8 to 68. There
were particularly high numbers of boys with repeat sizes of 20 (10.67%)
and 23 (7.35%). The mean repeat size for FRAXE is 17.41 (S.D. 3.94), with
median of 16 and range of 0 to 61. There is a relatively high degree of
variation of the FRAXA repeat size particularly and we suggest the
extensive data available from the ALSPAC study opens up areas of
research into understanding phenotypes associated with relatively
unexplored repeat sizes. This could be particularly interesting for the lower
repeat sizes occurring with high frequency at FRAXA in this population. As
the data can be linked to exposures and phenotypes, it will provide a
resource for researchers worldwide.
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Introduction
The mutation associated with the Fragile X syndrome is within a 
CGG trinucleotide repeat array in the FMR1 gene, identified in 
1991 (Pieretti et al., 1991). The gene is located in the Xq27.3 region 
of the long arm of the X chromosome (Lubs, 1969; Sutherland, 
1979; Sutherland, 1977). The array contains a variable number 
of repeats, and each repeat size is regarded in genetic terms 
as an FMR1 allele (often referred to as a FRAXA allele) 
(reviewed in Pembrey et al., 2001). Similarly, FRAXE syn-
drome is caused by the expansion of a GCC repeat in the 
FMR2 gene (Knight et al., 1993). FRAXA allele classes are 
categorised by the number of repeats and defined as full 
mutation (>200), premutation (61–200), intermediate (41–60), 
common (11–40) and minimal (<11) (Murray et al., 1996). FRAXE 
allele classes are similarly defined, but are slightly different 
for intermediate (31–60) and common (11–31) classes.
Full mutations of FRAXA (> 200 CGG repeats with silenc-
ing of the FMR1 gene) are more common than those of FRAXE 
(Knight et al., 1996); in the literature, the population preva-
lence of full FRAXA mutations in males was estimated to be 
between 1 in 4000 and 1 in 5000, though acknowledging biases 
due to informed consent (Chandrasekara et al., 2017; Youings 
et al., 2000). For females the estimation is lower, at around 1 in 
8000 (Crawford et al., 1999). FRAXE full mutation prevalence 
in males has been estimated at 1 in 23,400 (Youings et al., 2000).
Individuals with a full mutation inherit it from a female who 
carries a full mutation or premutation (Pembrey et al., 2001). 
Around a third of female gene carriers are intellectually impaired, 
usually less severely than males (Pembrey et al., 2001). Most 
males with Fragile X syndrome (full mutation) have a severe to 
moderate degree of mental impairment (Pembrey et al., 2001). 
The full mutation type for FRAXE syndrome has been found to 
result in much milder impairment than the FRAXA phenotype 
(Crawford et al., 1999). 
In females, there is a well-established phenotypic effect of 
FRAXA premutation sized alleles of an increased risk of pre-
mature ovarian failure (Chandrasekara et al., 2017; Macpherson 
et al., 2003; Youings et al., 2000). There is also some evidence 
of an increased incidence of late-onset neurological disorder 
characterised by tremor and ataxia (FXTAS) in premutation 
males, with around 40% at risk, and, to a lesser extent, females, at 
~8% (Chandrasekara et al., 2017; Hagerman et al., 2001; 
Hagerman et al., 2004). Several studies have suggested that 
intermediate alleles at both FRAXE and FRAXA may have a 
role in cognitive impairment in boys, more reliably for FRAXA 
(Murray et al., 1996; Youings et al., 2000). However, this find-
ing has not been replicated in some other multinational studies 
(Youings et al., 2000). Specifically, a study investigating 
FRAXA intermediate alleles in ALSPAC data even found a 
significant deficiency of special educational needs (SEN) cases in 
boys with FRAXA intermediate expansions (Ennis et al., 2006).
An issue within the literature is that the definitions of the bounda-
ries of classes of repeat numbers are sometimes different across 
studies (e.g. changes over time due to knowledge base 
or differing clinical definitions), thus making it harder to 
compare frequencies (see Cornish et al., 2008; Pembrey et al., 
2001; Youings et al., 2000). The general variation of frequencies 
of repeat sizes is often overlooked, as are phenotypic associations 
with relatively low repeat sizes (particularly differences within 
allele classes). Additionally, some studies have found a corre-
lation between the length of repeats and degree of phenotype, 
even within allele classes (Cornish et al., 2008).
Here we present a dataset of repeat size frequencies at FRAXA 
and FRAXE of boys from the ALSPAC study, which could 
provide an important resource for researchers internationally.
Materials and methods
Ethical approval and consent
Ethical approval for the study was obtained from the ALSPAC 
Ethics and Law Committee and the Local Research Ethics Com-
mittees (Birmingham, 2018). Informed consent for the use of 
data via questionnaires and clinics was obtained from partici-
pants following the recommendations of the ALSPAC Ethics 
and Law Committee at the time. Questionnaires were completed 
by parents in their own homes and the return of a questionnaire 
to the study offices was interpreted as giving tacit consent 
to the study. Full details of the approvals obtained are avail-
able from the ethics pages of the study website (http://www. 
bristol.ac.uk/alspac/researchers/research-ethics/). Study members 
have the right to withdraw their consent for elements of the 
study or from the study entirely at any time. Consent for 
biological samples was collected in accordance with the Human 
Tissue Act (2004).
The ALSPAC sample
The ALSPAC study was designed to include all pregnant moth-
ers with an expected date of delivery between 1st April 1991 
and 31st December 1992 living in a specific area in the South 
West Regional Health Authority of England (Boyd et al., 2013; 
Fraser et al., 2013). The number of enrolled pregnant moth-
ers was 14541, which resulted in 13988 infants who survived to 
one year. When the oldest children were approximately seven 
years of age, an attempt was made to bolster the initial sample 
with eligible cases who had failed to join the study originally. 
Including these additional children results in 14,901 infants 
who survived to one year. Data collection largely consisted of 
self-completion questionnaires (principally based on psycho-
social factors, physical environments and health) filled in by 
mothers, partners, children and teachers. The study methodol-
ogy (Golding et al., 2001), enrolment and response rates are 
given in detail on the study website (http://bristol.ac.uk/
alspac/index.html). Please note that the study website contains 
details of all the data that is available through a fully search-
able data dictionary and variable search tool (http://www.bris-
tol.ac.uk/alspac/researchers/our-data/). The data presented here 
on maternal age, parity, parental education levels and socio-
economic status were obtained during pregnancy from maternal 
self-completion questionnaires. 
Sample collection
The DNA of children in the study was gathered by the ALSPAC 
study team; samples were collected from 5275 males in total 
(Ennis et al., 2006). Permission for DNA extraction was obtained 
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as written consent from the study mothers during pregnancy 
(for cord blood), as well as in ALSPAC clinics for venepunc-
ture blood taken at 43 months, 61 months, seven years and nine 
years. Some samples were extracted from buccal wash when 
the child did not consent to venepuncture. The ALSPAC study team 
double coded all samples for anonymity.
DNA amplification and analysis
Cord blood samples were collected in heparin at birth and 
stored at -70°C for five to eight years before DNA extraction 
(Jones et al., 2000). Blood samples from children at 43 or 61 
months were stored for one month to two years before extrac-
tion (Jones et al., 2000). Samples from children at seven and nine 
years were stored at -20°C for up to three weeks before DNA 
extraction (Jones et al., 2000). The samples were provided to 
the laboratory as 250ng aliquots in 96 well plates with eight 
wells on each plate left empty for laboratory control, consisting 
of DNA with known CGG repeat number and water controls 
(Ennis et al., 2006). When there was both a cord blood and 
clinic sample were available for the same boy, the clinic sam-
ple was used to maximise genotyping efficiency, as heparin can 
inhibit PCR, and to minimise maternal contamination issues 
(Ennis et al., 2006). The DNA was amplified using fluorescent 
PCR (involving fluorescently labelled oligonucleotide primers) 
across the CGG FRAXA repeat and GCC FRAXE repeat. This 
took place in the Wessex Regional Genetics Laboratory.
Two multiplex PCR reactions were carried out, the details of 
which are given elsewhere (Jones et al., 2000; Murray et al., 
1996; Youings et al., 2000). For both multiplex reactions, prod-
ucts were denatured and separated on a polyacrylamide urea gel 
and then run on an ABI 373A Stretch machine for eight hours at 
40 W, 2500 V and 35 mA (Murray et al., 1996). The gel data 
were analysed on 672 GENESCAN software (ABI/Perkin Elmer) 
and then imported into GENOTYPER software (ABI/Perkin 
Elmer) to assign alleles (Murray et al., 1996).
Data processing
Genotype data were returned to the ALSPAC Study (Univer-
sity of Bristol). The anonymised dataset is in SPSS format and 
analysis was carried out using a combination of SPSS (version 
11) statistical software and SAS (SAS Institute Inc., Cary, N.C.). 
The dataset includes: the ALSPAC pregnancy identifier (ano-
nymised), whether the pregnancy was singleton/twins/triplets, 
the category of FRAXA/E repeat size, and the number of repeats 
at FRAXA/E.
Dataset
In all, there were 5087 children for whom the number of repeats 
(RPTs) at FRAXA and 5070 at FRAXE were assessed. Of 
these, 192 were additional cases recruited at seven years old. 
The proportion of the 7676 boys in the study population for 
whom RPT data were obtained was 66.3% for FRAXA and 
66.1% for FRAXE. Those who were missed included: those for 
whom permission had not been given and thus DNA was not 
available (2401); those where the assay had not worked (164), 
including those with high levels of premutations and the 
full mutation; and additionally, where there was not enough 
DNA, or samples had a heterozygous genotype indicating the 
possibility of two X chromosomes or maternal contamination 
(27) (Ennis et al., 2006). As PCR is not possible for amplifi-
cation of large premutations/full mutations, these individuals 
are not included in this dataset.
Table 1 shows the percentage of boys for whom there is 
FRAXA repeat data within each category of sociodemographic 
attributes. Among the parents of boys in the ALSPAC study, 
FRAXA repeat information was slightly more likely to be avail-
able when the education levels achieved by the mother and the 
father were higher, the father’s occupation was of a higher social 
Table 1. Proportion (and percentage) of boys for whom 
the number of FRAXA repeats (RPTs) have been 
obtained by sociodemographic attributes of their 
parents. The education level ranges from less than O-level/
GCSE (A) to degree level qualification (E). The social class 
categories are as previously defined (‘Standard occupation 
classification’, 1990).
Variable Proportion with 
FRAXA RPTs
% with 
FRAXA RPTs
Maternal education
A (lowest) 755 /1322 57.1
B 418 /641 65.2
C 1577 /2237 70.5
D 1139 /1439 79.2
E (highest) 618 /812 76.1
Paternal education
A (lowest) 974 /1612 60.4
B 343 /515 66.6
C 950 /1334 71.2
D 1129 /1579 71.5
E (highest) 863 /1143 75.5
Social class (father’s 
Occupation
I (Higher professional) 479 /630 76.0
II 1373 /1916 71.7
IIINm 436 /619 70.4
IIIM 1187 /1779 66.7
IV 361 /535 67.5
V (unskilled) 110 /163 67.5
Maternal age
<20 151 /327 46.2
20–24 778 /1378 56.5
25–29 1892 /2813 67.3
30–34 1397 /1998 69.9
35+ 547 /766 71.4
Parity of  the mother
0 1997 /2988 66.8
1 1596 /2368 67.4
2 683 /989 69.1
3+ 255 /404 63.1
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Table 2. The frequency of boys in each class of FRAXA 
repeats. This is also expressed as a percentage of the number 
of boys for which the number of repeats (RPT) data is available.
Class of FRAXA repeat Frequency Percentage
Minimal (<11) <5 0.06
Common (11-40) 4,913 96.58
Intermediate (41-60) 168 3.3
Premutation (61-200) unmethylated <5 0.06
Total 5,087 100
class, and the mothers were older. However, there was no 
difference in availability by the number of pregnancies the mother 
had had where the baby reached viability (parity). The patterns 
in regard to FRAXE were similar.
The error rate for FRAXA and FRAXE genotypes (i.e. CGG 
repeat number difference >1) were 0.52% and 0.65% respec-
tively, calculated by comparing duplicate samples. Duplicates 
that were not matched and samples which failed to amplify were 
categorised as failed (Ennis et al., 2006).
FRAXA
The mean number of repeats (RPTs) at FRAXA is 28.92 (S.D. 
5.44), with a median of 30 and a range of 8 to 68. Using the 
arbitrary definitions in the literature (Murray et al., 1996), only 
three of the boys would be categorised as having a premutation 
(defined as 61-200 RPTs) and 168 as intermediary (41-60 RPTs) 
(Table 2). In all, approximately 11% have an RPT >32. The 
frequency distribution also has a substantially high number 
of individuals with repeat numbers of 20 (10.67%) and 23 
(7.35%) disrupting the normal distribution around the mean 
(Figure 1).
Figure 1. Distribution of FRAXA repeats. Graph of the distribution of number of repeats at FRAXA, for all boys for which valid number of 
repeats (RPT) data was obtained.
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Table 3. The frequency of boys in each class of FRAXE 
repeats. In the third column, this is expressed as a percentage 
of the number of boys for which the number of repeats (RPT) 
data is available.
Class of FRAXE repeat Frequency Percentage
Minimal (<11) 43 0.85
Common (11-30) 4983 98.28
Intermediate (31-60) 43 0.85
Premutation (61-200) unmethylated <5 0.02
Total 5070 100
Figure 2. Distribution of FRAXE repeats. Graph of the distribution of number of repeats at FRAXE, for all boys for which valid number of 
repeats (RPT) data was obtained.
FRAXE
The mean number of RPTs at FRAXE is 17.41 (S.D. 3.94), with 
a median of 16 and a range of 0 to 61. Using the definitions in 
the literature (Murray et al., 1996), one of the boys would be 
classed as having a premutation (Table 3). There is less vari-
ation in the FRAXE RPTs compared to the FRAXA RPTs 
(Figure 2), but a suggestion of a bimodal distribution.
Strengths and limitations of the dataset
One of the strengths of this data is that it includes a very large 
number of individuals and we present the general variation 
across RPT sizes, which is sometimes overlooked in the lit-
erature. Additionally, given the extensive information gathered 
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about children in the ALSPAC study, there is potential to look 
at the RPT size variation to ascertain if there are any correla-
tions with other variables. This could open up interesting ave-
nues of research into the phenotypes associated with different 
RPT sizes, particularly for the allele categories rarely studied 
in the literature so far (such as ‘minimal’ and ‘common’) and 
for the relatively unexpected peak seen in the FRAXA data 
around 20/23 RPTs (Figure 1). Very few studies have looked 
at phenotypes associated with very low numbers of repeats at 
FRAXA or FRAXE. A few smaller studies did find associa-
tion of alleles of less than 26 repeats at FRAXA with increased 
risk of developing fertility problems, behavioural problems and/
or having children with developmental disability or psychiat-
ric illness; this has not been replicated by larger studies and as 
such remains controversial (Kraan et al., 2018).
There was some bias in that the boys without RPT data were 
more likely to have had mothers who were younger, less well 
educated and of lower social class (Table 1). This needs to be 
taken into account in further studies, including subsequent 
correlations with variables from the ALSPAC data. Another 
limitation is that ascertaining repeat sizes of large premutation or 
full mutation alleles was not possible and these data are not 
represented in the dataset. 
Data availability
Underlying data
ALSPAC data access is through a system of managed open 
access. The steps below highlight how to apply for access to the 
data included in this paper and all other ALSPAC data. Please 
read the ALSPAC access policy (http://www.bristol.ac.uk/
media-library/sites/alspac/documents/researchers/data-access/
ALSPAC_Access_Policy.pdf), which describes the process of 
accessing the data and biological samples in detail and outlines 
the costs associated with doing so.
1.    You may also find it useful to browse our fully search-
able research proposals database (https://proposals.
epi.bristol.ac.uk/), which lists all research projects that 
have been approved since April 2011.
2.    Please submit your research proposal (https://propos-
als.epi.bristol.ac.uk/) for consideration by the ALSPAC 
Executive Committee using the online process. You will 
receive a response within 10 working days to advise 
you whether your proposal has been approved.
       If you have any questions about accessing data, 
please email: alspac-data@bristol.ac.uk (data) or 
bbl-info@bristol.ac.uk (samples). 
     The ALSPAC data management plan (http://www.bristol.
ac.uk/media-library/sites/alspac/documents/research-
ers/data-access/alspac-data-management-plan.pdf) 
describes in detail the policy regarding data sharing, which 
is through a system of managed open access.
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Clark   describes the alleles that were obtained from a remarkable sample, the ALSPAC study whichet al.
followed the offspring of women who delivered between April 1,1991 and December 31, 1992. PCR
testing was done for FRAXA and FRAXE alleles and reported here. Only boys were studied and only
about 66% had successful results. The reasons for a low uptake included a lack of consent, which is
understandable, but there were 164 samples where the assay did not work either because it was a high
premutation or a full mutation or not enough DNA or a heterogeneous genotype with possibly 2 Xs or
maternal contamination. They need to clarify the numbers that had a large premutation or a full mutation
to help with the prevalence figures and if possible use Southern Blot testing or newer PCR techniques to
clarify who had a full mutation. For the data that they did obtain there was a large number with a lower
repeat in the FRAXA group, specifically 10.67% with 20 repeats and 7.35% with 23 repeats which is
unusual compared to previous studies. It seems that the authors have missed a great opportunity to
correlate these low repeat numbers with the cognitive data that seems to be available at multiple time
points in the ALSPAC study. The authors should do this if possible.
It is difficult to compare their prevalence results to previous studies because the standard definition of the
premutation as 55 to 200 repeats is not used. Instead the premutation is defined as 61-200 and the
intermediate is 41-60. Most other studies will use 41 to 54 repeats for the intermediate or gray zone. It
would be helpful for them to define these categories in the introduction and use the standard definitions.
Under ALSPAC sample first paragraph “enrollment” is misspelled.
Overall this study demonstrates a high level of low CGG repeats in the FRAXA analysis but they have the
opportunity to correlate this with the clinical data including cognitive testing and they need to do this.
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